New pill could help kids with dwarfism grow better
NCT ID NCT07169279
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an oral drug called infigratinib in infants and children under 3 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth and body proportions. The trial has several phases to find the right dose and then compare the drug to a placebo over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infigratinib (oral drug)
What this could lead to
If successful, this could provide a daily oral treatment to improve growth and body proportions in young children with achondroplasia.
What could go wrong
This is an early Phase 2 trial with only 77 participants, so results may not confirm benefit. Side effects are still being studied, and the drug requires daily dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Eastern Ontario Research Institute
RECRUITINGOttawa, Ontario, K1H 8L1, Canada
-
Guy's and Saint Thomas' NHS Foundation Trust
NOT_YET_RECRUITINGLondon, SE1 7EH, United Kingdom
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21218, United States
-
KK Women's and Children's Hospital
RECRUITINGSingapore, 2298899, Singapore
-
Manchester University NHS Foundation Trust
NOT_YET_RECRUITINGManchester, M13 9WL, United Kingdom
-
Murdoch Children's Research Institute
RECRUITINGParkville, Victoria, 3052, Australia
-
NHS Greater Glasgow and Clyde
RECRUITINGGlasgow, G3 8SJ, United Kingdom
-
Paediatric Clinical Research Unit at Oslo University Hospital
RECRUITINGOslo, 0372, Norway
-
Sheffield Children's NHS Foundation Trust
RECRUITINGSheffield, S10 2TH, United Kingdom
-
UCSF Benioff Children's Hospital
RECRUITINGOakland, California, 94609, United States
-
Unidad de Cirugia Artroscopica (UCA)
NOT_YET_RECRUITINGVitoria-Gasteiz, 01010, Spain
-
University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic
RECRUITINGMadison, Wisconsin, 53705, United States
-
Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine
RECRUITINGMontreal, Quebec, H3T 1C5, Canada